CCN5 mitigates myosteatosis and counteracts sarcopenia by promoting mitochondrial biogenesis and enhancing LD-Mt interactions through dual pathways, positioning it as a promising therapeutic target for muscle aging and sarcopenia.
Shen et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: